Does Medicare Cover Weight Loss Drugs Like Ozempic or Wegovy?

The base rule: why weight-loss-only prescribing is excluded

Federal law has long excluded drugs used specifically "for weight loss" from Medicare Part D coverage — a statutory exclusion that sits alongside similar carve-outs for certain cosmetic and fertility drugs. This exclusion hasn't been repealed, and changing it fundamentally would require an act of Congress, not just a CMS policy decision. This is the single most important fact to understand before anything else in this guide: the underlying law is still the same law it's been for years.

This exclusion applies specifically to the purpose a drug is prescribed for, not to any particular drug by name. This is exactly why the same medication can be covered in one situation and denied in another — the law draws its line around the prescribing reason, not the chemical compound itself. Understanding this framing early makes the rest of this guide considerably easier to follow, since nearly every nuance described below traces back to this single distinction between a drug's identity and its prescribed purpose.

What Part D has always covered

The confusion around these drugs largely comes down to the fact that the same active ingredient often has multiple FDA-approved uses, each with its own coverage status. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and have been covered under Part D for years when prescribed for that purpose. Separately, Wegovy gained an additional FDA-approved indication for reducing cardiovascular risk in overweight or obese patients with established cardiovascular disease — Part D can cover Wegovy under this specific indication, often with prior authorization confirming the qualifying diagnosis. In January 2025, Ozempic gained a further supplemental indication for reducing the risk of kidney function decline in patients with type 2 diabetes and chronic kidney disease, opening another qualifying pathway.

This pattern of a drug gaining new FDA-approved indications over time isn't unique to GLP-1 medications, but it's especially consequential here given how many separate qualifying conditions have accumulated for a relatively small set of active ingredients. The practical upshot for a beneficiary: the specific diagnosis code and documentation behind a prescription genuinely matter as much as the drug name itself when it comes to whether Part D will pay for it. A prescription written simply as "for weight loss," even for a drug that technically has a covered indication for something else, can still be denied if the qualifying diagnosis isn't clearly documented.

The 2025 policy attempt that didn't go through

A proposed federal rule would have gone further, reinterpreting obesity itself as a chronic disease eligible for broader anti-obesity medication coverage under Medicare and Medicaid — a genuinely significant potential shift. That broader rule was ultimately not finalized. If you'd heard Medicare was about to cover weight-loss drugs universally, that specific proposal is what didn't happen — worth knowing since outdated coverage of the story still circulates online.

What's genuinely new: the GLP-1 Bridge program

Instead of the broader rule, the administration reached a separate arrangement with drug manufacturers that produced something new: the Medicare GLP-1 Bridge, a temporary demonstration program that operates outside the normal Part D benefit structure. Starting July 1, 2026 and running through December 31, 2027, eligible beneficiaries enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage can access specific weight-loss-indicated GLP-1 medications for a $50 monthly copay.

This is genuinely historic — it's the first time Medicare has covered a GLP-1 medication for weight loss alone, without requiring a separate qualifying condition like diabetes. But it's explicitly temporary and limited in scope, not a permanent restructuring of the underlying exclusion. A program called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is scheduled to follow once the Bridge program ends, suggesting this transitional period is intended to lead toward some further structure, though the specifics of that follow-on program were still being finalized at the time of writing.

It's worth understanding why this arrangement took the form of a temporary pilot rather than a permanent policy change. Structuring it as a demonstration program allowed CMS to move relatively quickly, without needing the full notice-and-comment rulemaking process that a permanent regulatory change typically requires, and without needing new legislation from Congress. This flexibility comes with a real tradeoff: pilot programs can be modified, extended, or ended by the same administrative process that created them, which is exactly why confirming current status directly rather than assuming this piece's description remains accurate indefinitely is worth doing, especially as the program's scheduled end date approaches.

Which specific drugs qualify — and which don't

The Bridge program covers a specific, narrow list: Wegovy (both injection and tablet forms), Zepbound KwikPens specifically, and Foundayo (orforglipron, a newer oral GLP-1). It does not include Zepbound's single-use pens or vials, and it doesn't include Ozempic at all, since Ozempic remains FDA-approved for diabetes rather than weight loss specifically — a detail that surprises many people given how closely the two drugs are associated with each other in general conversation.

A related but separate development: drug price negotiation

In a separate process entirely, CMS selected Ozempic, Rybelsus, and Wegovy for its second round of Medicare drug price negotiations under the Inflation Reduction Act. The negotiated price for a 30-day supply is set at $274, effective in 2027 — though actual out-of-pocket cost sharing for an individual beneficiary will typically be considerably lower than that negotiated list price. It's worth understanding this is a pricing mechanism, not a coverage expansion on its own: it lowers the cost of these drugs when they're already covered under an existing indication, rather than creating new weight-loss coverage by itself.

This distinction matters for anyone comparing Medigap alongside their prescription drug planning, since Medigap plans don't typically address Part D drug costs at all — they help with Part A and Part B cost-sharing specifically, meaning the price negotiation and Bridge program described here operate entirely independently of whichever Medigap decision a beneficiary has made.

What to do next

• Confirm which FDA-approved indication your prescription is actually written for.
• If you have diabetes, cardiovascular disease, or chronic kidney disease alongside your weight loss goals, ask whether your existing Part D coverage already applies.
• If your interest is weight loss specifically, ask your Part D plan directly whether you qualify for the GLP-1 Bridge program.
• Confirm which specific drug formulation (KwikPen versus vial, for instance) is actually included before assuming coverage applies.
• Don't assume Medicaid coverage exists in your state — check directly, since coverage has actually been narrowing in several states.

If weight management is connected to a broader health goal — managing an existing mental health condition, for instance, where medication and lifestyle changes often intersect — it's worth discussing your full treatment picture with your prescriber rather than treating each medication decision in isolation. Coordinating care across multiple conditions can sometimes reveal a documented, qualifying diagnosis for standard Part D coverage that a narrower, single-issue conversation might miss entirely.

Common questions about Medicare and weight loss drugs

Have a question that isn't answered below? Our full Medicare FAQ hub covers broader eligibility, enrollment, and cost questions, and our guide on appealing a Medicare claim denial covers what to do if a GLP-1 prescription claim is denied.